Table 2.
NME1 gene variants and breast cancer survival
| Marker | Breast cancer mortality |
Disease -free survival a |
||||
|---|---|---|---|---|---|---|
| cases | events | HR (95% CI) b | cases | events | HR (95% CI) b | |
| All patients | ||||||
| rs16949649 | ||||||
| TT | 382 | 63 | 1.0 (ref) | 365 | 91 | 1.0 (ref) |
| CC/CT | 751 | 160 | 1.4 (1.1–1.9) | 728 | 213 | 1.3 (1.0–1.6) |
| CC | 213 | 42 | 1.4 (0.9–2.0) | 207 | 53 | 1.0 (0.7–1.4) |
| CT | 538 | 118 | 1.4 (1.1–2.0) | 521 | 160 | 1.3 (0.8–1.6) |
| rs2302254 | ||||||
| CC | 631 | 125 | 1.0 (ref) | 608 | 165 | 1.0 (ref) |
| CT/TT | 500 | 99 | 1.2 (0.9–1.5) | 483 | 140 | 1.3 (1.0–1.6) |
| CT | 411 | 82 | 1.2 (0.9–1.6) | 398 | 121 | 1.3 (1.1–1.7) |
| TT | 89 | 17 | 1.1 (0.7–1.8) | 85 | 19 | 1.0 (0.6–1.6) |
| Patients with TNM stage 0–II | ||||||
| rs16949649 | ||||||
| TT | 314 | 36 | 1.0 (ref) | 304 | 57 | 1.0 (ref) |
| CC/CT | 622 | 107 | 1.7 (1.2–2.5) | 610 | 156 | 1.5 (1.1–2.1) |
| CC | 179 | 30 | 1.6 (1.0–2.6) | 177 | 42 | 1.3 (0.9–2.0) CT |
| CT | 443 | 77 | 1.8 (1.2–2.6) | 433 | 114 | 1.6 (1.2–2.2) |
| rs2302254 | ||||||
| CC | 504 | 72 | 1.0 (ref) | 491 | 103 | 1.0 (ref) |
| CT/TT | 429 | 71 | 1.3 (0.9–1.8) | 420 | 110 | 1.4 (1.1–1.8) |
| CT | 351 | 56 | 1.3 (0.9–1.8) | 343 | 93 | 1.5 (1.1–2.0) |
| TT | 78 | 15 | 1.3 (0.7–2.2) | 77 | 17 | 1.0 (0.6–1.7) |
| Patients with TNM stage III–IV | ||||||
| rs16949649 | ||||||
| TT | 44 | 18 | 1.0 (ref) | 38 | 23 | 1.0 (ref) |
| CC/CT | 80 | 38 | 1.1 (0.6–2.0) | 69 | 41 | 1.1 (0.6–2.0) |
| CC | 19 | 9 | 1.3 (0.5–2.9) | 15 | 8 | 1.1 (0.5–2.6) |
| CT | 61 | 29 | 1.0 (0.5–2.0) | 54 | 33 | 1.1 (0.6–2.0) |
| rs2302254 | ||||||
| CC | 82 | 37 | 1.0 (ref) | 73 | 43 | 1.0 (ref) |
| CT/TT | 43 | 20 | 0.9 (0.5–1.6) | 35 | 22 | 1.1 (0.6–2.0) |
| CT | 37 | 18 | 0.9 (0.5–1.7) | 32 | 20 | 1.0 (0.6–1.8) |
| TT | 6 | 2 | 1.0 (0.2–4.5) | 3 | 2 | 3.9 (0.9–18.1) |
a
Defined as risk of breast cancer relapse, metastasis, and death.
b
Adjusted by age, education, TNM stage, radio therapy, chemotherapy, tamoxifen use, ER and PR status. Patients who died of causes other than breast cancer were excluded in the breast cancer mortality analyses.